Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124073433 | 12407343 | 3 | F | 20160705 | 20160526 | 20160801 | PER | US-PFIZER INC-2016275205 | PFIZER | 52.00 | YR | F | Y | 68.00000 | KG | 20160801 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124073433 | 12407343 | 1 | PS | PREMARIN | ESTROGENS, CONJUGATED | 1 | 0.5 G, DAILY, EVERY NIGHT | Y | 20216 | .5 | G | VAGINAL CREAM | |||||||
| 124073433 | 12407343 | 2 | C | ZOLOFT | SERTRALINE HYDROCHLORIDE | 1 | 150 MG, 1X/DAY | 0 | 150 | MG | QD | ||||||||
| 124073433 | 12407343 | 3 | C | WELLBUTRIN XL | BUPROPION HYDROCHLORIDE | 1 | 300 MG, 1X/DAY | 0 | 300 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124073433 | 12407343 | 1 | Vulvovaginal dryness |
| 124073433 | 12407343 | 2 | Depression |
| 124073433 | 12407343 | 3 | Anxiety |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124073433 | 12407343 | Feeling abnormal | |
| 124073433 | 12407343 | Headache | |
| 124073433 | 12407343 | Mood altered |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124073433 | 12407343 | 1 | 20160521 | 0 |